Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-27T22:37:12.065Z Has data issue: false hasContentIssue false

Pharmacotherapy in patients with cluster a personality disorders

Published online by Cambridge University Press:  16 April 2020

B.A. Völlm
Affiliation:
Section of Forensic Mental Health, University of Nottingham, Nottingham, UK
S. Farooq
Affiliation:
Wolverhampton City PCT, Wolverhampton, UK
M. Ferriter
Affiliation:
Nottinghamshire Health Care Nhs Trust, Nottingham, UK
H. Jones
Affiliation:
Nottinghamshire Health Care Nhs Trust, Nottingham, UK
N. Smailagic
Affiliation:
Nottinghamshire Health Care Nhs Trust, Nottingham, UK
N. Khalifa
Affiliation:
Nottinghamshire Health Care Nhs Trust, Nottingham, UK
N. Huband
Affiliation:
Nottinghamshire Health Care Nhs Trust, Nottingham, UK
S. Gibbon
Affiliation:
St Andrew's Healthcare, Northampton, UK
J. Stoffers
Affiliation:
University of Freiburg Medical Center, Freising, Germany
C. Duggan
Affiliation:
Section of Forensic Mental Health, University of Nottingham, Nottingham, UK
K. Lieb
Affiliation:
University Medical Center Mainz, Mainz, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Among the 10 categories of personality disorders (PDs), interventions for antisocial and borderline personality disorder are best studied. However, the remaining PDs also pose major problems in everyday health care settings. People affected often additionally present with Axis-I disorders such as substance-related, mood or anxiety disorders, and are among those most difficult to treat. Cluster A PDs (paranoid, schizoid, schizotypal) are of particular significance as some authors argue that they may be part of a continuum of mental disorders and be considered as sub-syndrome of schizophrenia

Methods

In the context of Cochrane Collaboration reviews for Cluster A, B and C PDs, exhaustive literature searches were completed to identify the current RCT evidence for PD treatments. Retrievals were assessed and evaluated by two reviewers independently and trials for Cluster A PD were identified.

Results

Only very few (under five) RCTs specifically for Cluster A PDs were identified. Some studies reported on mixed PD samples but it was not always possible to extract data specifically for Cluster A disorders. Participants mostly also suffered from Axis-I disorders. Reported outcomes also focus on Axis-I disorder outcomes or general measures such as overall functioning rather than specific PD symptoms.

Conclusions

The current evidence for psychpathological treatment of Cluster A PD is sparse and does not allow for distinct treatment recommendations. Symptom-driven treatment regimes as suggested by several guidelines are not supported by current evidence.

Type
S26-04
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.